马蔺子素对鼻咽癌患者远期生存的影响  

Influence of irisquinone on long-term su rvive for nasopharyngela carcinoma

作　　者：李曙平[1] 吴煌坚[1] 叶金辉[1] 罗凤玲[1] 练英妮[1] 黄肇云[1] 

机构地区：[1]广东省肇庆市第一人民医院肿瘤科,526021

出　　处：《广州医药》2005年第3期43-45,共3页Guangzhou Medical Journal

摘　　要：目的评价马蔺子素(安卡)在鼻咽癌放射治疗中的应用价值。方法158例经病理证实为鼻咽癌的患者被随机分为马蔺子素联合放射治疗组(治疗组)和单纯放射治疗组(对照组),两组放射治疗方法、剂量相同,治疗组在放射治疗的同时服用安卡110mg/次,每天2次,直至放射治疗结束。结果治疗组远期生存率明显高于对照组,两组差异有显著意义(χ2=3.9378,P<0.05);治疗组复发率17.95%,明显低于对照组的32.50%(χ2=4.4228,P<0.05);治疗组死于局部复发者亦明显低于对照组,分别为11.10%和28.75%(χ2=5.0172,P<0.05);而两组远期后遗症的发生率无明显差异。结论马蔺子素联合放射治疗鼻咽癌,能明显提高鼻咽癌的局部控制率,减少了局部复发和提高了远期生存率,同时未增加正常组织的放射损伤,是一个较理想的放射增敏剂。Objective To evaluate the ut ility value of Irisquinone in combinatio n with radiotherapy in patients with nas opharyngeal carcinoma(NPC). Methods 158 cases of pathological proven NPC were d ivided at random into sutdy group and co ntrol group. The dosage and method of ra diation were identical in the two groups . The patients of study group were treat ed with radiotherapy combined with Irisq uinone 110 mg twice daily through treatm ent. Results The Long-term survival rat e in study group were higher than those in control group which was a different s ignificantly between two groups(χ2=3,937 8,P<0.05). Relapse rate in study group was 17.95%. which were decreased signif icantly than them in control group(χ2=4 .4228,P<0.05). The death rate because o f local relapse in study group were lowe r than these in control group, 11.10% an d 28.75%, respectively (χ2=5.0172,P<0.05). No difference of Long-term sequea l between two group. Conclusion Combina tion of Irisquinon and radiotherapy can improve significantly local control rate of NPC, decrease local relapse and impr ove long-term survival rate. meanwhile, radiative damage was not increased. Iris qinor is a ideal radio sensitization dra g.

关 键 词：马蔺子素 鼻咽癌患者 远期生存率 放射治疗方法 局部复发 治疗组 远期后遗症 局部控制率 放射增敏剂 对照组 应用价值 病理证实 同时服用 放射损伤 正常组织 复发率 发生率 安卡 

分 类 号：R739.63[医药卫生—肿瘤]